BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 27, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/24 cls
Aastrom Biosciences Inc. (NASDAQ:ASTM) Roth Capital Partners Joseph Pantginis Downgrade Neutral (from buy) -12% $1.60
Pantginis also lowered his target to $2.30 from $7 on a lack of value-driving catalysts through the remainder of the year. Pantginis remains confident in a positive outcome for the U.S. Phase III REVIVE trial evaluating intramuscular ixmyelocel-T to treat critical limb ischemia (CLI). However, he believes the timeline for enrolling REVIVE is at the far end of the company's 18-24 months guidance and may be further revised. Ixmyelocel-T is an autologous cell therapy made from bone...

Read the full 668 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >